New growth hormone injection enters first human safety tests
NCT ID NCT07016802
First seen Apr 15, 2026 · Last updated May 15, 2026 · Updated 2 times
Summary
This early-stage study tests whether a new medicine called GenSci134 is safe and tolerable for people. It involves healthy adults and patients with adult growth hormone deficiency, a condition where the body doesn't make enough growth hormone. Participants receive either the study drug, a placebo, or an active comparator to check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT GROWTH HORMONE DEFICIENCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Third Hospital
RECRUITINGBeijing, Beijing Municipality, 100083, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.